{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-217376","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.321424+00:00","generated_at":"2026-06-24T01:33:59.941677+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cytek Q2 revenue $40.2M (+32% YoY); net loss of $0.7M vs prior-year net income $2.7M","bullets":["Revenue $40.2M, up 32% YoY; gross profit $24.6M (61% margin) vs $19.7M (65% margin) prior year.","Operating loss $0.9M vs operating income $3.8M in Q2 2021; net loss $0.7M vs prior net income $2.7M.","Adjusted EBITDA $4.8M flat YoY; installed base 1,356 instruments (130 placed in quarter).","Full-year 2022 revenue guidance reaffirmed: closer to high end of $160M-$168M range.","Received CE mark for cFluor reagents and TBNK kit for European clinical market."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-217376","json":"https://secwatch.observer/filing/0001193125-22-217376.json","markdown":"https://secwatch.observer/filing/0001193125-22-217376.md","text":"https://secwatch.observer/filing/0001193125-22-217376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312522217376/0001193125-22-217376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312522217376/d363001d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:33:59.941677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}